Smith & Nephew PDMR DRIP buys at £12.4048 on Nov 7, 2025

Smith & Nephew plc reported routine share acquisitions by its CEO and senior executives under the Company’s Dividend Re‑Investment Plan.

Rhea-AI Filing Summary

Smith & Nephew plc reported routine share acquisitions by its CEO and senior executives under the Company’s Dividend Re‑Investment Plan. The purchases followed the 2025 interim dividend and were executed on 7 November 2025 on the London Stock Exchange (XLON) at £12.4048 per share.

Participants included Chief Executive Officer Deepak Nath (2,624.43651 shares), President, Sports Medicine Scott Schaffner (746.79305), President, Advanced Wound Management and Global Commercial Operations Rohit Kashyap (427.09066), President, Orthopaedics Craig Gaffin (197.25944), Chief Quality & Regulatory Affairs Officer Mizanu Kebede (4.1729), and President, Global Operations Paul Connolly (394.41542).

The transactions relate to ordinary shares of USD 0.20 each (ISIN: GB0009223206) and were disclosed under UK Market Abuse Regulation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SNN disclose in this Form 6-K?

Smith & Nephew plc disclosed PDMR and director purchases of ordinary shares via the Company’s Dividend Re‑Investment Plan following the 2025 interim dividend.

When were the Smith & Nephew (SNN) PDMR transactions executed?

All reported transactions took place on 7 November 2025.

At what price were the SNN DRIP shares acquired?

Each acquisition was executed at £12.4048 per share.

Which SNN executives participated and what were their volumes?

Examples include Deepak Nath 2,624.43651 shares and Scott Schaffner 746.79305 shares, with additional PDMRs listed.

Where were the SNN transactions conducted?

The transactions were executed on the London Stock Exchange (XLON).

What class of SNN security was involved?

Ordinary shares of USD 0.20 each, ISIN GB0009223206.

Under which regulation were these SNN transactions disclosed?

They were notified under the UK Market Abuse Regulation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/10/2025 - 09:41 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the

Securities Exchange Act of 1934

November 10, 2025

Commission File Number 001-14978

SMITH & NEPHEW plc

(Registrant’s name)

Building 5, Croxley Park, Hatters Lane

Watford, England, WD18 8YE

 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ✔         Form 40-F __

SMITH & NEPHEW PLC

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

Reason for the notification
Initial notification /Amendment	Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name	Smith & Nephew plc
LEI	213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument	Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code	ISIN: GB0009223206
Nature of the transaction	Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2025 interim dividend payment on 7 November 2025.
Date of Transaction	2025 - 11 - 07
Place of Transaction	London Stock Exchange (XLON)

Name (Position)	Director / PDMR	Price (£)	Volume	Aggregated information
Scott Schaffner (President, Sports Medicine)	PDMR	12.4048	746.79305	N/A Single Transaction
Deepak Nath (Chief Executive Officer)	Director	12.4048	2624.43651	N/A Single Transaction
Rohit Kashyap (President, Advanced Wound Management and Global Commercial Operations)	PDMR	12.4048	427.09066	N/A Single Transaction
Craig Gaffin (President, Orthopaedics)	PDMR	12.4048	197.25944	N/A Single Transaction
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer)	PDMR	12.4048	4.1729	N/A Single Transaction
Paul Connolly (President, Global Operations)	PDMR	12.4048	394.41542	N/A Single Transaction

Philip Horner

Deputy Company Secretary

Smith & Nephew plc

Tel:  +44 (0)1923 477100

LEI:    213800ZTMDN8S67S1H61

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Smith & Nephew plc
		(Registrant)
Date: November 10, 2025	By:	/s/ Helen Barraclough
		Helen Barraclough
		Company Secretary